Regulatory T cells in cancer immunotherapy

Current Opinion in Immunology

Volumn 27, Issue 1, 2014, Pages 1-7

  Nishikawa, Hiroyoshi ^a   Sakaguchi, Shimon ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOGLOBULIN G4; NY ESO 1 ANTIGEN; TRANSCRIPTION FACTOR FOXP3;

ANTIGEN RECOGNITION; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CYTOKINE RESPONSE; HUMAN; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIGENS, NEOPLASM; DISEASE PROGRESSION; HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES, REGULATORY;

EID: 84892448554     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2013.12.005     Document Type: Review

References (66)

1. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., Knuth A., Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254:1643-1647.
2. Kawakami Y., Rosenberg S.A. Human tumor antigens recognized by T-cells. Immunol Res 1997, 16:313-339.
3. Scanlan M.J., Gure A.O., Jungbluth A.A., Old L.J., Chen Y.-T. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002, 188:22-32.
4. Boon T., Coulie P.G., Van den Eynde B.J., van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006, 24:175-208.
5. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004, 10:909-915.
6. Gnjatic S., Nishikawa H., Jungbluth A.A., Gure A.O., Ritter G., Jager E., Knuth A., Chen Y.-T., Old L.J. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res 2006, 95:1-30.
7. Dougan M., Dranoff G. Immune therapy for cancer. Annu Rev Immunol 2009, 27:83-117.
8. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006, 6:295-307.
9. Nishikawa H., Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer 2010, 127:759-767.
10. Sharma P., Wagner K., Wolchok J.D., Allison J.P. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 2011, 11:805-812.
11. Wing K., Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 2010, 11:7-13.
12. + T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999, 163:5211-5218.
13. + regulatory T cells in the human immune system. Nat Rev Immunol 2010, 10:490-500.
14. + T cells expressing the FoxP3 transcription factor. Immunity 2009, 30:899-911.
15. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J.R., Zhang L., Burow M., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10:942-949.
16. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005, 102:18538-18543.
17. Alvaro T., Lejeune M., Salvado M.T., Bosch R., Garcia J.F., Jaen J., Banham A.H., Roncador G., Montalban C., Piris M.A. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005, 11:1467-1473.
18. + T-cell subpopulations in head and neck cancers. Clin Cancer Res 2006, 12:465-472.
19. + T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009, 27:186-192.
20. + regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci U S A 2013, 110:17945-17950.
21. Faget J., Biota C., Bachelot T., Gobert M., Treilleux I., Goutagny N., Durand I., Leon-Goddard S., Blay J.Y., Caux C., et al. Early detection of tumor cells by innate immune cells leads to Treg recruitment through CCL22 production by tumor cells. Cancer Res 2011, 71:6143-6152.
22. Facciabene A., Peng X., Hagemann I.S., Balint K., Barchetti A., Wang L.P., Gimotty P.A., Gilks C.B., Lal P., Zhang L., et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells. Nature 2011, 475:226-230.
23. + T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity. Cancer Res 2012, 72:4351-4360.
24. + regulatory T cells and their ligands: implications for immunotherapy. Immunity 2004, 20:107-118.
25. Vence L., Palucka A.K., Fay J.W., Ito T., Liu Y.J., Banchereau J., Ueno H. Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2007, 104:20884-20889.
26. + regulatory T cells: implications for immunotherapy. Cancer Res 2008, 68:6350-6359.
27. Bonertz A., Weitz J., Pietsch D.H.K., Rahbari N.N., Schlude C., Ge Y.Z., Juenger S., Vlodavsky I., Khazaie K., Jaeger D., et al. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest 2009, 119:3311-3321.
28. Fourcade J., Sun Z., Kudela P., Janjic B., Kirkwood J.M., El-Hafnawy T., Zarour H.M. Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoire. J Immunol 2010, 184:6709-6718.
29. + regulatory T cells. J Exp Med 2005, 201:681-686.
30. + regulatory T cells induced by an agonist self-peptide. Nat Immunol 2001, 2:301-306.
31. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004, 22:531-562.
32. + T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells. Cancer Res 2009, 69:4335-4345.
33. Chen Y.-T., Scanlan M.J., Sahin U., Tureci O., Gure A.O., Tsang S., Williamson B., Stockert E., Pfreundschuh M., Old L.J. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 1997, 94:1914-1918.
34. Danke N.A., Koelle D.M., Yee C., Beheray S., Kwok W.W. Autoreactive T cells in healthy individuals. J Immunol 2004, 172:5967-5972.
35. + helper T cell responses in cancer patients. Blood 2005, 106:1008-1011.
36. + T cells following peptide vaccination. J Immunol 2006, 176:6340-6346.
37. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155:1151-1164.
38. Onizuka S., Tawara I., Shimizu J., Sakaguchi S., Fujita T., Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res 1999, 59:3128-3133.
39. Attia P., Maker A.V., Haworth L.R., Rogers-Freezer L., Rosenberg S.A. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 2005, 28:582-592.
40. Dannull J., Su Z., Rizzieri D., Yang B.K., Coleman D., Yancey D., Zhang A., Dahm P., Chao N., Gilboa E., et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005, 115:3623-3633.
41. Jacobs J.F., Punt C.J., Lesterhuis W.J., Sutmuller R.P., Brouwer H.M., Scharenborg N.M., Klasen I.S., Hilbrands L.B., Figdor C.G., de Vries I.J., et al. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. Clin Cancer Res 2010, 16:5067-5078.
42. Rech A.J., Mick R., Martin S., Recio A., Aqui N.A., Powell D.J., Colligon T.A., Trosko J.A., Leinbach L.I., Pletcher C.H., et al. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci Transl Med 2012, 4:134ra162.
43. Williams M.A., Bevan M.J. Effector and memory CTL differentiation. Annu Rev Immunol 2007, 25:171-192.
44. + regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002, 3:135-142.
45. + regulatory T cells. J Exp Med 2005, 202:885-891.
46. Mitsui J., Nishikawa H., Muraoka D., Wang L., Noguchi T., Sato E., Kondo S., Allison J.P., Sakaguchi S., Old L.J., et al. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clin Cancer Res 2010, 16:2781-2791.
47. + T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 2005, 105:2845-2851.
48. Piconese S., Valzasina B., Colombo M.P. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med 2008, 205:825-839.
49. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
50. Robert C., Thomas L., Bondarenko I., O'Day S., M D J., Garbe C., Lebbe C., Baurain J.F., Testori A., Grob J.J., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364:2517-2526.
51. Leach D.R., Krummel M.F., Allison J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996, 271:1734-1736.
52. Quezada S.A., Peggs K.S., Curran M.A., Allison J.P. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006, 116:1935-1945.
53. Bulliard Y., Jolicoeur R., Windman M., Rue S.M., Ettenberg S., Knee D.A., Wilson N.S., Dranoff G., Brogdon J.L. Activating Fcγ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med 2013, 210:1685-1693.
54. Mark J.S., John J.E., Michael Q., Karla A.H., Timothy C., Mohan S., Alan J.K. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regualtory T cells. Cancer Immunol Res 2013, 1:32-42.
55. Simpson T.R., Li F., Montalvo-Ortiz W., Sepulveda M.A., Bergerhoff K., Arce F., Roddie C., Henry J.Y., Yagita H., Wolchok J.D., et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013, 210:1695-1710.
56. Hodi F.S., Butler M., Oble D.A., Seiden M.V., Haluska F.G., Kruse A., Macrae S., Nelson M., Canning C., Lowy I., et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A 2008, 105:3005-3010.
57. hi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A 2008, 105:14987-14992.
58. + regulatory T cell function. Science 2008, 322:271-275.
59. Ise W., Kohyama M., Nutsch K.M., Lee H.M., Suri A., Unanue E.R., Murphy T.L., Murphy K.M. CTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms. Nat Immunol 2010, 11:129-135.
60. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P., Drake C.G., Camacho L.H., Kauh J., Odunsi K., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465.
61. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., Powderly J.D., Carvajal R.D., Sosman J.A., Atkins M.B., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
62. Hamid O., Robert C., Daud A., Hodi F.S., Hwu W.J., Kefford R., Wolchok J.D., Hersey P., Joseph R.W., Weber J.S., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013, 369:134-144.
63. Kryczek I., Liu R., Wang G., Wu K., Shu X., Szeliga W., Vatan L., Finlayson E., Huang E., Simeone D., et al. FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res 2009, 69:3995-4000.
64. Berger R., Rotem-Yehudar R., Slama G., Landes S., Kneller A., Leiba M., Koren-Michowitz M., Shimoni A., Nagler A. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008, 14:3044-3051.
65. hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005, 106:2018-2025.
66. Walter S., Weinschenk T., Stenzl A., Zdrojowy R., Pluzanska A., Szczylik C., Staehler M., Brugger W., Dietrich P.Y., Mendrzyk R., et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2011, 17:1094-1100.